Biohub, funded by the Chan Zuckerberg Initiative, will launch its fourth round of Rare As One funding this fall, focusing on patient-led groups working on rare pulmonary, immune diseases, and rare cancers. The program has invested over $150 million to help patient organizations build research infrastructure and advance clinical trials. Biohub is also expanding its partnership with Every Cure, a nonprofit using AI to identify drug repurposing opportunities, aiming to accelerate patient-centered research. This initiative reflects Biohub's broader effort to integrate AI in disease research and drug discovery, supporting over 94 patient-led organizations to date.
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
ARCpoint Inc. announced it will likely miss the July 29, 2026 deadline to file its annual financial statements and related reports due to a lack of funds to pay auditors. The company has applied for a Management Cease Trade Order (MCTO) and awaits ap...
The Rosen Law Firm is investigating potential securities claims against Putnam Investment Management, LLC, alleging that the company may have provided misleading business information to investors. Investors who purchased Putnam stock-based mutual fun...
Blackrock CEO Larry Fink expressed strong optimism about market prospects over the next year, citing technology-driven productivity and margin expansion as key growth drivers. He noted that overall financial leverage is much lower than during the 200...
Velvet token fell about 18% in one day amid heavy selling, yet it remains the top gainer among the top 100 tokens with a 571% increase over the past 90 days. Despite $24 million exiting its perpetual Futures market in two weeks, bullish sentiment per...
